|
 |
Volume 3, Number 8 (August 2006) | |||||
Letter from the Editor |
|||||
474 |
Keeping it practical—and patient-focused Wilshire Oncology Medical Group, Inc., La Verne, CA Timely and practicall—that characterizes this month’s lineup of articles, with a spotlight on breast cancer. Our Community Dialogue highlights a controversial issue. Two nationally recognized breast experts help us think through the problem of which women with early estrogen receptor-positive breast cancer can forgo chemotherapy in favor of hormone therapy alone.
|
||||
Community Dialogue |
|||||
487 |
Can some ER-positive breast cancer patients forgo chemotherapy? Recent studies suggest that some ER-positive breast cancer patients might safely forgo chemotherapy. Two of the researchers on the forefront of this work discuss the implications—and the difficulties of making decisions based on imperfect ER testing data.
|
||||
Current Clinical Trials |
|||||
494 |
The TAILORx trial: individualized options for treatment Albert Einstein College of Medicine, Montefiore-Einstein Cancer Center, Bronx, NY By integrating state-of-the-art diagnostic tests into clinical decision making, the TAILORx trial is designed to individualize treatments for ER-positive breast cancer. This article describes the trial and how clinicians can enroll their patients.
|
||||
Economics/Practice Management |
|||||
501 |
Savvy purchasing The West Clinic, Memphis, TN A veteran practice administrator and purchasing expert outlines his top techniques for fine-tuning your purchasing skills in tight economic times. The article includes practical suggestions on keeping track of supplies and inventory and the best negotiating tactics.
|
||||
Controversies in Patient Management |
|||||
507 |
The evolving role of laparoscopy in the surgical management of oncology patients Pennsylvania Hospital, University of Pennsylvania Health System, Philadelphia Minimally invasive surgery offers several important advantages to the cancer patient needing surgery: less bleeding; less trauma; less risk of incisional hernias, wound adhesions, and postoperative infection; and quicker, less painful recovery. Although not all centers offer laparoscopy, it’s important for clinicians and their patients to be aware of the options.
|
||||
Original Contributions |
|||||
519 |
Novel agents for chronic myeloid leukemia: from imatinib to dasatinib and nilotinib: overcoming resistance Oregon Health and Science University, Center for Hematologic Malignancies, Portland, OR In patients with CML, kinase mutations are the most common mechanism of acquired drug resistance. The degree of resistance is variable, and the T315I mutation resists all Abl kinase inhibitors. Novel second-generation Abl inhibitors dasatinib and nilotinib are extremely promising agents for use alone or in combination with imatinib in these patients.
|
||||
525 |
Genetic approaches to sarcoma diagnosis Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE Bone and soft-tissue sarcomas are diagnostically challenging. Increasing recognition of the specific genetic and chromosomal abnormalities inherent in these tumors and the growing use of cytogenetic and molecular genetic procedures have significantly improved the accuracy of sarcoma diagnosis and provided valuable information on the histopathogenesis of these neoplasms.
|
||||
Quality Care |
|||||
530 |
Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice Advanced Medical Specialties, Miami, FL, and Florida Cancer Consultants, Cancer Research Network, Plantation, FL Evidence-based oncology practice guidelines recommend primary prophylaxis with a granulocyte colony-stimulating factor for patients at moderate to high risk of febrile neutropenia (FN). Often overlooked as a serious consequence of routine cancer treatment, FN can lead to disruption of scheduled chemotherapy; increased risk of infection, morbidity, and mortality; and higher resource utilization costs. Preventing FN should be a quality standard, and nurses are well qualified to lead such efforts.
|
||||
Having Your Say |
|||||
483 |
With cost pressures up, will nurses be targeted again? Many nurses fled the bureaucracy of hospitals and their staff cuts by moving to private oncology practices. Christopher Friese, a nurse researcher, now worries that lower Medicare reimbursements and belt tightening will mean déjà vu all over again.
|
||||
Technology |
|||||
514 |
CME in cyberspace When you can save time, money, and aggravation, who wouldn’t prefer to get CME credits online?
|
||||
Washington Update |
|||||
539 |
Congress hears testimony on reimbursement concerns In July, Congress heard testimony on the concerns of cancer clinics across the country. One focus of the hearing: access to IVIG for immunocompromised patients.
|
||||
On Submitting Articles |
|||||
540 |
Guide for authors
|
||||
© 2006 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
|||||
44 kb